Movement Alert｜DualityBio-B Falls 5.61% in Regular Trading, Biotech Sector Under Broad Selling Pressure as Buybacks Fail to Stem Decline

Market Focus06-11

On June 11, DualityBio-B fell 5.61% in regular trading, trading at 165.6 HKD/share, with trading volume of approximately 42.53 million HKD.

On the news front, despite the company announcing on June 10 that its STAR Market IPO coaching had passed Shanghai CSRC verification and continuing share buybacks, selling pressure persisted. The company repurchased 10,000 shares on June 10 at a cost of approximately 1.674 million HKD. A prior rebound of over 6% on June 5 — driven by ASCO clinical data and intensive buyback activity — proved short-lived, with the stock retreating steadily from its recent high.

The broader biotechnology sector experienced systematic selling pressure, with BeiGene down 5.71%, Akeso down 4.38%, SKB Bio down 4.53%, 3SBio down 3.76%, and Innovent Bio down 3.30%, amplifying individual stock weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170981598?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 10:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170981598","market":"hk","top_or_hot":-1,"title":"Movement Alert｜DualityBio-B Falls 5.61% in Regular Trading, Biotech Sector Under Broad Selling Pressure as Buybacks Fail to Stem Decline","media":"Market Focus","content":"<p><p>On June 11, DualityBio-B fell 5.61% in regular trading, trading at 165.6 HKD/share, with trading volume of approximately 42.53 million HKD.</p><p>On the news front, despite the company announcing on June 10 that its STAR Market IPO coaching had passed Shanghai CSRC verification and continuing share buybacks, selling pressure persisted. The company repurchased 10,000 shares on June 10 at a cost of approximately 1.674 million HKD. A prior rebound of over 6% on June 5 — driven by ASCO clinical data and intensive buyback activity — proved short-lived, with the stock retreating steadily from its recent high.</p><p>The broader biotechnology sector experienced systematic selling pressure, with BeiGene down 5.71%, Akeso down 4.38%, SKB Bio down 4.53%, 3SBio down 3.76%, and Innovent Bio down 3.30%, amplifying individual stock weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DualityBio-B Falls 5.61% in Regular Trading, Biotech Sector Under Broad Selling Pressure as Buybacks Fail to Stem Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DualityBio-B Falls 5.61% in Regular Trading, Biotech Sector Under Broad Selling Pressure as Buybacks Fail to Stem Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-11 10:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 11, DualityBio-B fell 5.61% in regular trading, trading at 165.6 HKD/share, with trading volume of approximately 42.53 million HKD.</p><p>On the news front, despite the company announcing on June 10 that its STAR Market IPO coaching had passed Shanghai CSRC verification and continuing share buybacks, selling pressure persisted. The company repurchased 10,000 shares on June 10 at a cost of approximately 1.674 million HKD. A prior rebound of over 6% on June 5 — driven by ASCO clinical data and intensive buyback activity — proved short-lived, with the stock retreating steadily from its recent high.</p><p>The broader biotechnology sector experienced systematic selling pressure, with BeiGene down 5.71%, Akeso down 4.38%, SKB Bio down 4.53%, 3SBio down 3.76%, and Innovent Bio down 3.30%, amplifying individual stock weakness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1170981598","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170981598","pubTimestamp":1781145437,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 11, DualityBio-B fell 5.61% in regular trading, trading at 165.6 HKD/share, with trading volume of approximately 42.53 million HKD.On the news front, despite the company announcing on June 10...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提示|DualityBio-B常规交易下跌5.61%，生物科技板块因回购未能阻止跌势而面临广泛抛售压力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On June 11, DualityBio-B fell 5.61% in regular trading, trading at 165.6 HKD/share, with trading volume of approximately 42.53 million HKD.On the news front, despite the company announcing on June 10 that its STAR Market IPO coaching had passed Shanghai CSRC verification and continuing share buybacks, selling pressure persisted. The company repurchased 10,000 shares on June 10 at a cost of approximately 1.674 million HKD. A prior rebound of over 6% on June 5 — driven by ASCO clinical data and intensive buyback activity — proved short-lived, with the stock retreating steadily from its recent high.The broader biotechnology sector experienced systematic selling pressure, with BeiGene down 5.71%, Akeso down 4.38%, SKB Bio down 4.53%, 3SBio down 3.76%, and Innovent Bio down 3.30%, amplifying individual stock weakness.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170981598","isCrawlerRequest":true}